Moderna MRNA
$254.19 +$12.73 (+5.27%)
Market closed · Nov 6, 8:20 pm ET · Last extended-hours $256.92 +1.07%
Open$245.40
Prev close$241.46
Day range$237.86 – $267.50
Volume16.33M
Market cap$101.48B
P/E (TTM)–
Dividend yield–
MRNA Stock News
Headlines matching Moderna or the MRNA ticker, most recent first.
- Beta Pharma (300558.SZ): Currently has no relevant layout in the mRNA field.
- HK Stock Market Alert | Jitai Technology-P (07666) surges over 20% in afternoon session; cumulative gain exceeds 30% in two days of inclusion in the Stock Connect. Global AI + mRNA vaccine sector accelerates. Positive
- Hualan Biological Engineering Inc. (002007.SZ): Controlled subsidiary receives approval notice for clinical trials of novel influenza mRNA vaccine Positive
- Form 144 | Moderna(MRNA.US) Officer Proposes to Sell 4.69 Million in Common Stocks
- Nano Holdings: New research findings on mRNA therapeutics have been announced by the group led by Professor Akihisa Iitaka.
- mRNA‑related stocks lead gains: CanSino Biologics tops the pack, while Moderna's mRNA neoantigen therapy is set to debut at the ESMO Congress. Positive
- Hong Kong Stock Market Movers | CSPC Pharma (01093) rises nearly 6% following consecutive announcements of R&D progress, including developments in mRNA cancer vaccines and recombinant protein vaccines. Positive
- CanSino Biologics: Currently developing mRNA-based prophylactic vaccines and therapeutic biologics, as well as related delivery systems.
- CanSino Biologics: Currently developing mRNA-based preventive vaccines and therapeutic biologics, along with related delivery systems.
- mRNA cancer vaccines enter the confirmatory validation window; the underlying index of the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) rose nearly 4% today.
- Rothschild & Co Redburn Initiates Moderna(MRNA.US) With Sell Rating, Announces Target Price $81
- J.P. Morgan Maintains Moderna(MRNA.US) With Sell Rating
- DBS Maintains Moderna(MRNA.US) With Hold Rating, Raises Target Price to $150 Positive
- Argus Research Upgrades Moderna(MRNA.US) to Buy Rating, Announces Target Price $180 Positive
- US Stock Market Update: Moderna (MRNA.US) Surges Over 10% After Multiple Wall Street Banks Raise Price Targets Positive
No comments yet — be the first to weigh in on MRNA.
Sign in to join the discussion.